ProShare Advisors’s 10x Genomics TXG Stock Holding History

ProShare Advisors’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$458K	Sell	21,565 -3,760	-15%	-$75.2K	﹤0.01%	1114
2025 Q4	$413K	Buy	25,325 +2,908	+13%	+$43.9K	﹤0.01%	1246
2025 Q3	$262K	Sell	22,417 -3,386	-13%	-$44.1K	﹤0.01%	1523
2025 Q2	$299K	Buy	+25,803	New	+$235K	﹤0.01%	1443
2022 Q1	–	Sell	-2,300	Closed	-$343K	–	2302
2021 Q4	$343K	Buy	2,300 +152	+7%	+$23.3K	﹤0.01%	1706
2021 Q3	$313K	Sell	2,148 -534	-20%	-$91.7K	﹤0.01%	1519
2021 Q2	$525K	Buy	2,682 +1,307	+95%	+$237K	﹤0.01%	1510
2021 Q1	$249K	Buy	+1,375	New	+$237K	﹤0.01%	1909

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ProShare Advisors's TXG Position: Q1 2026 in Review

ProShare Advisors reduced its 10x Genomics (TXG) stake by 15% in Q1 2026, selling an estimated $75.2K and leaving 21,565 shares worth $458K. The position accounts for ﹤0.01% of the portfolio, ranked #1114.

ProShare Advisors first reported a position in TXG in Q1 2021 and has held it in 8 quarters since. The position peaked at $525K in Q2 2021. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

ProShare Advisors held 21,565 shares of 10x Genomics worth $458K as of Q1 2026.
ProShare Advisors sold 3,760 10x Genomics shares in Q1 2026, an estimated $75.2K.
10x Genomics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1114 holding.
ProShare Advisors first reported a position in 10x Genomics in Q1 2021 and has held it in 8 quarters since.
ProShare Advisors's 10x Genomics position peaked at $525K in Q2 2021.
329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.